CIK 0001607678 · Large accelerated filer
Viking Therapeutics, Inc.
Sign in to watch- Ticker
- VKTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 461073877
- Phone
- 858-704-4660
- Business address
- 9920 PACIFIC HEIGHTS BLVD, SUITE 500, SAN DIEGO, CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-03 | ZANTE GREG Chief Financial Officer | Grant or award | +44,533 | 193,901 | ||
| 2025-01-03 | ZANTE GREG Chief Financial Officer | Grant or award | +21,667 | 215,568 | ||
| 2025-01-03 | ZANTE GREG Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +37,200 | 37,200 | ||
| 2025-01-02 | MACARTNEY LAWSON Director | Grant or award · Stock Option (Right to Buy) | +18,800 | 18,800 | ||
| 2025-01-02 | SINGLETON J MATTHEW Director | Grant or award · Stock Option (Right to Buy) | +18,800 | 18,800 | ||
| 2025-01-02 | Rowland Charles A Jr Director | Grant or award · Stock Option (Right to Buy) | +18,800 | 18,800 | ||
| 2025-01-02 | FOEHR MATTHEW W Director | Grant or award · Stock Option (Right to Buy) | +18,800 | 18,800 | ||
| 2025-01-02 | Rouan Sarah Kathryn Director | Grant or award · Stock Option (Right to Buy) | +18,800 | 18,800 | ||
| 2024-11-08 | MACARTNEY LAWSON Director | Option exercise | +2,000 | $5.80 | $12K | 49,965 |
| 2024-11-08 | MACARTNEY LAWSON Director | Sale | −2,000 | $68.67 | $137K | 47,965 |
| 2024-11-08 | MACARTNEY LAWSON Director | Option exercise · Stock Option (Right to Buy) | −2,000 | 20,000 | ||
| 2024-10-28 | ZANTE GREG Chief Financial Officer | Option exercise 10b5-1 | +12,750 | $7.77 | $99K | 199,802 |
| 2024-10-28 | ZANTE GREG Chief Financial Officer | Option exercise 10b5-1 | +4,251 | $4.68 | $20K | 204,053 |
| 2024-10-28 | ZANTE GREG Chief Financial Officer | Option exercise 10b5-1 | +26,000 | $5.80 | $151K | 230,053 |
| 2024-10-28 | ZANTE GREG Chief Financial Officer | Option exercise 10b5-1 | +51,000 | $8.52 | $435K | 281,053 |
| 2024-10-28 | ZANTE GREG Chief Financial Officer | Sale 10b5-1 | −49,672 | $74.56 | $3.7M | 231,381 |
| 2024-10-28 | ZANTE GREG Chief Financial Officer | Sale 10b5-1 | −18,620 | $75.79 | $1.4M | 212,761 |
| 2024-10-28 | ZANTE GREG Chief Financial Officer | Sale 10b5-1 | −9,265 | $76.94 | $713K | 203,496 |
| 2024-10-28 | ZANTE GREG Chief Financial Officer | Sale 10b5-1 | −23,082 | $77.68 | $1.8M | 180,414 |
| 2024-10-28 | ZANTE GREG Chief Financial Officer | Sale 10b5-1 | −15,825 | $78.69 | $1.2M | 164,589 |
Page 5 of 27 · 528 trades